Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest lung cancer Stories

2014-03-27 12:30:55

A St. Jude Children's Research Hospital-led study identified two adult cancer drugs with potential to improve treatment of a high-risk childhood brain tumor; the drugs are now part of a pediatric clinical trial MEMPHIS, Tenn., March 27, 2014 /PRNewswire-USNewswire/ -- The quest to improve survival of children with a high-risk brain tumor has led St. Jude Children's Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other...

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-03-26 16:25:02

TORONTO, March 26, 2014 /CNW/ - The most comprehensive review of the performance of Canada's cancer control systems reveals that some older Canadians with colon, lung or breast cancer are not receiving guideline-recommended radiation and chemotherapy at the same rate as younger patients with these cancers. This age-related disparity may be explained by a number of factors. For example, older people are more likely to have other acute and or chronic health problems, which could...

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...

2014-03-26 08:28:35

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /PRNewswire/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX:CXR) (OTCQX: CHEHF) announced today that its subsidiary Pinnacle Biologics, Inc. (Pinnacle), a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental...

2014-03-24 23:27:51

Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancer announced today that P2045, the Company's lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). Orphan...

2014-03-20 23:02:41

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. Sacramento, CA (PRWEB) March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The...

2014-03-20 23:01:42

Florida Hospital Tampa will feature clinical experts in the field of cancer on Tuesday, March 25th to educate the community on the latest information in cancer prevention, treatment, support and therapy. Tampa, Fl (PRWEB) March 20, 2014 Florida Hospital Tampa is hosting “A Cancer Symposium” with a focus on the three big c’s- breast, GI, and lung cancers to educate the community on prevention, treatment, support and therapy. This event is free to the public and will take place at...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

2014-03-15 08:21:28

DALLAS, March 15, 2014 /PRNewswire/ -- ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store. According to Epilepsy Therapeutics in Asia Pacific Markets to...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »